

Hematopoietic stem cell transplantation for patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a retrospective study of 21 patients from SFGM-TC centers

Nicolas Vallet,¹ Flore Sicre de Fontbrune,² Michaël Loschi,³ Deborah Desmier,⁴ Alban Villate,¹ Fiorenza Barraco,⁵ Patrice Chevallier,⁶ Louis Terriou,⁷ Ibrahim Yakoub-Agha,⁷ Annalisa Ruggeri,⁸ Mohamad Mohty,⁸ Natacha Maillard,⁴ Pierre-Simon Rohrllich,⁹ Patrice Ceballos,¹⁰ Stéphanie Nguyen,¹¹ Xavier Poiré,¹² Gaëlle Guillerm,¹³ Reza Tabrizi,¹⁴ Jonathan Farhi,¹⁵ Raynier Devillier,¹⁶ Marie-Thérèse Rubio,¹⁷ Gérard Socié² and Régis Peffault de Latour² on behalf of the Société Francophone de Greffe de Moelle et Thérapie Cellulaire

¹Hematology Department, Tours, France; ²Hematology Department, Saint Louis Hospital, Paris, France; ³Hematology Department, Rouen, France; ⁴Hematology Department, Poitiers, France; ⁵Hematology Department, Lyon, France; ⁶Hematology Department, Nantes, France; ⁷Hematology Department, Lille, France; ⁸Hematology Department, Saint Antoine Hospital, Paris, France; ⁹Hematology Department, Nice, France; ¹⁰Hematology Department, Montpellier, France; ¹¹Hematology Department, Pitié Salpêtrière Hospital, Paris, France; ¹²Hematology Department, Brussels, Belgium; ¹³Hematology Department, Brest, France; ¹⁴Hematology Department, Bordeaux, France; ¹⁵Hematology Department, Angers, France; ¹⁶Hematology Department, Institut Paoli Calmette, Marseille, France and ¹⁷Hematology Department, Nancy, France

Correspondence: regis.peffaultdelatour@aphp.fr
doi:10.3324/haematol.2017.182360

Supplementary Annexe: Collected data focused on the management of eculizumab at time of transplantation.

ECULIZUMAB BEFORE TRANSPLANTATION:

Date of last administration: / / (yyyy/mm/dd)

ECULIZUMAB AFTER TRANSPLANTATION:

- Discontinuation of eculizumab during transplant: Yes No

- eculizumab was used after transplant: Yes No

- If Eculizumab was used after transplantation, what was the indication?

- If eculizumab was used after transplant:

Dose of eculizumab : _____

Periodicity of eculizumab infusions : _____

Number of infusions: _____

Date of last administration: |__|_|_| (yyyy/mm/dd)

Reason for Eculizumab discontinuation :

Table S1: Supplementary characteristics of patients and conditioning regimens.

Indications	#	Biological findings at transplantation		Conditioning regimens			
		PNH clone size (%)	Elevated LDH	Type	Chemotherapy	ATG (mg/kg)	TBI (Gy)
Clonal evolution to MDS	1	90	Yes	NMA	Flu: 150 mg/m ² Bu: 6 mg/kg	5	-
Recurrent thrombosis	2	86	Yes	MAC	Bu: 9 mg/kg Cy: 150 mg/kg	5	-
Aplastic anemia PNH	3	20	Yes	NMA	Cy: 200 mg/kg	12.5	-
	4	73	Yes	NMA	Cy: 200 mg/kg	12.5	-
	5	46	No	NMA	Cy: 200 mg/kg	12.5	-
	6	84	Yes	NMA	Cy: 200 mg/kg	11	-
	7	17 ^a	No	NMA	Cy: 200 mg/kg	11.5	-
	8	58	No	NMA	Cy: 200 mg/kg	12.5	2
	9	79	No	NMA	Cy: 200 mg/kg	12.5	-
	10	†	No	NMA	Cy:†; Flu:†	-	-
	11	99	No	NMA	Cy 120 mg/kg Flu 120 mg/m ²	15	2
	12	28	Yes	NMA	Cy 120 mg/kg Flu 120 mg/m ²	-	2
	13	12 ^b	†	NMA	Cy 1.2 g/m ² Flu 120 mg/m ²	7.5	2
Transfused classical PNH	14	62	No	NMA	Cy 3 g/m ² Flu 150 mg/m ²	10	-
	15	99	No	NMA	Cy 200 mg/kg	12.5	-
	16	20	No	NMA	Cy 2.250 g/m ² Flu 90 mg/m ²	-	-

	17	88	Yes	NMA	Cy: 30 mg/kg Flu: 120 mg/m ²	10	-
		80	-	MAC	Flu: 120 mg/m ² Bu: 12 mg/kg	6	-
		†	-	NMA	Cy: 50 mg/kg Flu: 120 mg/m ²	-	2
	18	20	†	NMA	Cy 1200 mg/m ² Flu 120 mg/m ²	7.5	2
	19	95	Yes	NMA	Cy 200 mg/kg Flu 75 mg/m ²	3.7	2
		99	-	No	-	-	-
Non-transfused classical PNH	20	69	Yes	NMA	Melphalan 200 mg/m ²	-	-
	21	99	Yes	MAC	Bu 12 mg/kg Cy 200 mg/kg	-	-

^aPNH clone size at diagnosis was 85%; ^bPNH clone size at diagnosis was 58%; †Missing data; ATG: antithymocyte globulin; TBI: Total body irradiation; Flu: Fludarabine; Bu: Busulphan; Cy: Cyclophosphamide